Cumberland Pharmaceuticals (CPIX) presents a materially negative liquidation posture as of March 31, 2026, consistent with the MFFAIS-reported CLV of approximately negative $27.8M. Total assets of $71.0M are dominated by intangibles and inventory categories that attract steep haircuts under liquidation assumptions, while total liabilities of $49.7M are carried at face value. The arithmetic of the liquidation lens is straightforward: cash of $11.0M recovers at par; net AR of $14.3M haircuts to approximately $13.1M at 92%; total gross inventory of $15.3M haircuts to approximately $9.2M at 60%; net PP&E of $0.24M is de minimis; finite-lived intangibles of $12.8M and goodwill of $0.9M recover at zero under the 0% intangible assumption. Applying these haircuts yields a rough liquidation asset recovery of approximately $36M against $49.7M of face-value liabilities, implying negative equity recovery before any wind-down costs, contingent consideration obligations, or lease termination settlements. The operating lease liability of $4.8M (total present value) stands at face value in wind-down; the Broadwest lease runs through November 2035, with $7.2M in undiscounted future payments, representing a structurally sticky liability. The revolving credit facility carries $5.2M outstanding, collateralized by substantially all assets, giving Pinnacle Bank a senior secured claim that further subordinates equity. Combined contingent consideration liabilities for Vibativ and Sancuso total approximately $4.5M at face ($3.3M + $1.1M) and are treated at face in liquidation. Accounts payable plus other current liabilities of approximately $29.5M ($16.5M AP plus $13.0M other current) are the largest liability block. The dominant change since the prior 10-K is the April 22, 2026 subsequent event: an Asset Purchase Agreement with Apotex Inc. for $100M cash, covering substantially all FDA-approved commercial products plus associated inventory. If consummated, this transaction transforms the liquidation calculus entirely — the $100M consideration would clear all liabilities and generate material equity recovery — but as of the balance sheet date it remains pending shareholder approval and other closing conditions. The filing does not separately XBRL-tag the Apotex consideration amount or the transition services receivable ($150K/month plus reimbursements) or the $9M inventory reimbursement provision, though all are discussed in Note 12. A $3.3M net loss in Q1 2026 versus $1.3M net income in Q1 2025 reflects the revenue decline (no repeat of the $3.0M Vibativ China milestone), higher selling and marketing costs associated with the Talicia launch, and the new $0.15M co-commercialization investment loss on the Talicia equity stake. Net operating loss carryforwards of $44.1M (plus $8.5M from other sources) provide a deferred tax shield with no liquidation value given the zero-recovery assumption on deferred tax assets.
▼ Community Notes